Since CHEK2 germline mutation carriers are at a higher risk of developing CH (82–84), the entire HSC pool may undergo accelerated acquisition of additional mutations, such as CHEK2 biallelic or DNMT3A mutations, that drive transformation. Here, CHEK2 is linked to cyclic hematopoiesis.